INTRODUCTION: Between 1990 and 1998, tuberculin skin tests (TST) and isoniazid preventive therapy (IPT) were provided to injection drug users participating in the AIDS Linked to the Intravenous Experiences cohort. METHODS: A registry match was conducted with the AIDS Linked to the Intravenous Experiences cohort database and the Maryland State Department of Health and Mental Hygiene tuberculosis registry. RESULTS: Of 2010 participants, 1753 (74%) had a TST placed and read; 536 (31%) were positive. TST positivity was 16% in HIV positives; 39% in HIV negatives (P<0.01). Overall, 299 (56%) TST reactors started IPT; 165 (55%) completed 6 months. Three tuberculosis (TB) cases were diagnosed among HIV negatives (incidence rate=0.16/1000 person-years); 19 among HIV positives (1.94/1000 person-years; incidence rate ratio=12.3 (3.61-64.70). Within the entire cohort, TB rates were 0.81 per 1000 person-years for those not receiving IPT, 0.48 per 1000 person-years for those receiving any IPT, 0.29 per 1000 person-years for those completing at least 30 days, and 0 per 1000 person-years for completers. Ten cases of TB occurred in HIV-infected individuals with negative TSTs. DISCUSSION: IPT was associated with protection against TB, but uptake was modest. Although it is likely that TB incidence would have increased, especially in HIV-positive subjects, if the IPT program had not occurred, more significant declines in TB incidence in this population will require improved methods for ensuring uptake and completion of IPT and preventing disease in TST-negative individuals.
INTRODUCTION: Between 1990 and 1998, tuberculin skin tests (TST) and isoniazid preventive therapy (IPT) were provided to injection drug users participating in the AIDS Linked to the Intravenous Experiences cohort. METHODS: A registry match was conducted with the AIDS Linked to the Intravenous Experiences cohort database and the Maryland State Department of Health and Mental Hygiene tuberculosis registry. RESULTS: Of 2010 participants, 1753 (74%) had a TST placed and read; 536 (31%) were positive. TST positivity was 16% in HIV positives; 39% in HIV negatives (P<0.01). Overall, 299 (56%) TST reactors started IPT; 165 (55%) completed 6 months. Three tuberculosis (TB) cases were diagnosed among HIV negatives (incidence rate=0.16/1000 person-years); 19 among HIV positives (1.94/1000 person-years; incidence rate ratio=12.3 (3.61-64.70). Within the entire cohort, TB rates were 0.81 per 1000 person-years for those not receiving IPT, 0.48 per 1000 person-years for those receiving any IPT, 0.29 per 1000 person-years for those completing at least 30 days, and 0 per 1000 person-years for completers. Ten cases of TB occurred in HIV-infected individuals with negative TSTs. DISCUSSION: IPT was associated with protection against TB, but uptake was modest. Although it is likely that TB incidence would have increased, especially in HIV-positive subjects, if the IPT program had not occurred, more significant declines in TB incidence in this population will require improved methods for ensuring uptake and completion of IPT and preventing disease in TST-negative individuals.
Authors: Mark S Dworkin; Michael R Adams; David L Cohn; Arthur J Davidson; Susan Buskin; Carrie Horwitch; Anne Morse; Judy Sackoff; Melanie Thompson; Linda Wotring; Scott B McCombs; Jeffrey L Jones Journal: J Acquir Immune Defic Syndr Date: 2005-08-01 Impact factor: 3.731
Authors: Enrico Girardi; Caroline A Sabin; Antonella d'Arminio Monforte; Bob Hogg; Andrew N Phillips; M John Gill; Francois Dabis; Peter Reiss; Ole Kirk; Enos Bernasconi; Sophie Grabar; Amy Justice; Schlomo Staszewski; Gerd Fätkenheuer; Jonathan A C Sterne Journal: Clin Infect Dis Date: 2005-11-11 Impact factor: 9.079
Authors: C L Daley; P M Small; G F Schecter; G K Schoolnik; R A McAdam; W R Jacobs; P C Hopewell Journal: N Engl J Med Date: 1992-01-23 Impact factor: 91.245
Authors: Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland Journal: Lancet Date: 2010-07-31 Impact factor: 79.321
Authors: S Takuva; D Westreich; C N Menezes; L McNamara; I Sanne; L Page-Shipp; M Maskew Journal: Int J Tuberc Lung Dis Date: 2012-08-03 Impact factor: 2.373
Authors: Clíona Ní Cheallaigh; Ian Fitzgerald; Jacinta Grace; Gurmit Jagjit Singh; Nahla El-Eraki; Noel Gibbons; Joseph Keane; Thomas R Rogers; Susan Clarke; Colm Bergin Journal: PLoS One Date: 2013-01-30 Impact factor: 3.240
Authors: Andreas Sandgren; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anke Stuurman; Anouk Oordt-Speets; Marieke J van der Werf Journal: BMC Infect Dis Date: 2016-05-17 Impact factor: 3.090
Authors: Parastu Kasaie; Barun Mathema; W David Kelton; Andrew S Azman; Jeff Pennington; David W Dowdy Journal: PLoS One Date: 2015-12-17 Impact factor: 3.240